The Cochrane review included three randomised controlled trials. The first trail included 34 people with MS and researchers evaluated the effect of three drugs; methantheline bromide, flavoxate chloride and meladrazine tartrate.
The second study included 34 people who were treated with oxybutynin or propantheline.
Sixty-four people were included in the third trial and they were prescribed oral oxybutynin or atropine administered directly in to the bladder.
The authors of the review concluded that the current evidence does not support the use of anticholinergic drugs in the treatment of people with MS who have urinary symptoms.